Olmesartán Ratio (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olmesartán Ratio, is an angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is employed in the management of hypertension in adult patients. GNH USA supplies Olmesartán Ratio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartán Ratio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes. - Heart failure: used as part of combination therapy to improve outcomes in patients with reduced ejection fraction.

Adverse reactions to olmesartan are generally mild to moderate and vary with individual tolerance.

Common Side Effects: - Dizziness - Headache - Fatigue - Upper respiratory tract infection - Nausea - Diarrhoea

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation - Bullous pemphigoid

Olmesartan should be used with caution in specific clinical situations.

- Renal impairment: dose adjustment or monitoring may be required. - Hepatic impairment: monitor liver function tests. - Electrolyte disturbances: watch for potassium levels. - Concomitant use with potassium‑sparing diuretics: increased risk of hyper‑kalaemia. - Pregnancy and the women of the    ...

This ...